NuCana Announces ADS Ratio Change

Core Points - NuCana plc will change the ratio of its American Depository Shares (ADSs) from one ADS representing twenty-five ordinary shares to one ADS representing five thousand ordinary shares, effective August 11, 2025 [1][2] - This change is equivalent to a one-for-two hundred reverse ADS split and aims to support liquidity and regain compliance with Nasdaq's minimum bid price requirement [2][3] - The exchange will occur automatically for holders of uncertificated ADSs, while certificated holders must surrender their ADSs for cancellation [2] - The change will not affect shareholders' proportional equity interests, except for fractional ADSs, which will be aggregated and sold [2] - The trading price of ADSs is expected to increase proportionally, although no assurance can be given regarding the actual trading price post-change [3] Company Overview - NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes through its ProTide technology [4] - The company is developing new medicines, ProTides, to enhance the efficacy and safety of conventional chemotherapy agents [4] - NuCana's pipeline includes NUC-7738, currently in Phase 2 studies for advanced solid tumors, and NUC-3373, being evaluated in a Phase 1b/2 study for advanced solid tumors and lung cancer [4]